Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves System for Children with T1D

Medtronic plc news release; 2018 Jun 21

Medtronic plc has announced that the US Food and Drug Administration (FDA) has approved the use of the MiniMed 670G system in patients with type 1 diabetes aged ≥7 years.

This newest system by Medtronic features the company's most advanced SmartGuard technology and most accurate CGM—the Guardian Sensor 3—which work together to automate the delivery of a personalized amount of basal insulin every 5 minutes based on sensor glucose values. The system constantly self-adjusts to help avoid highs and lows, allowing patients to spend more Time in Range (the percentage of time spent in the optimal glycemic range of 70-180 mg/dL). In the US, Medtronic plc is headquartered in Minneapolis, MN.


Medtronic receives FDA approval of new pediatric indication for the MiniMed 670G Hybrid closed loop system in children ages 7-13. [news release]. Minneapolis, MN: Medtronic plc. June 21, 2018. Accessed July 6, 2018.